AI Built for Life Sciences
USDM’s AI Center of Excellence delivers the governance, strategy, validation, and managed services infrastructure that life sciences organizations need to adopt AI compliantly — from first pilot to enterprise scale. We are the only partner that governs AI AND builds it within GxP guardrails.
AI adoption in life sciences is accelerating — but governance is being outpaced.
The organizations winning in 2026 are those who built the compliance foundation first. USDM is purpose-built to be that foundation.
60% of pharma organizations are running GenAI pilots. Fewer than 6% of enterprise data meets FAIR standards. Fewer than half have formal AI ethics councils. The gap between AI experimentation and compliant enterprise deployment is where companies get hurt — and where USDM operates.
FDA’s AI/ML Action Plan, EU AI Act (enforcement live now), ICH E6 R3, and GAMP 5 Second Edition are all converging on the same requirement: AI in regulated contexts must be validated, monitored, and documented. Companies without governance by mid-2026 will have no runway to remediate.
The companies scaling AI fastest aren’t the ones with the most pilots — they’re the ones who solved governance first. Organizations establishing AI governance infrastructure now will hold a 12–18 month competitive advantage when regulators begin enforcement actions against unprepared organizations in 2026–2027.
Structured diagnostic across six AI maturity dimensions — strategy, governance, data, talent, deployment, and ethics. Produces a calibrated maturity score, peer benchmarks, shadow AI inventory, and a prioritized 90-day roadmap specific to your regulatory context.
Build the compliance infrastructure your AI portfolio requires. USDM implements the TRUST-AI governance framework — policies, SOPs, risk classification, and governance committee structure — establishing the controls that allow compliant AI deployment at scale.
With governance rails in place, USDM supports scaled AI deployment — PoC development, GxP-validated production systems, ongoing model monitoring, and AI Governance as a Service to maintain compliance as your AI portfolio grows.
25+ years exclusively in life sciences. Our consultants speak FDA’s language — CSA, Part 11, GAMP 5, ICH — because they’ve operated in these environments for decades. We don’t explain regulations; we navigate them daily.
We don’t just govern AI — we build it. USDM’s AI CoE delivers validated PoCs, GxP-compliant LLM pipelines, and production-ready AI systems. ProcessX on ServiceNow. AI-assisted validation. LLM output testing. End-to-end.
Delivery PODs operating in both US and EU markets — providing real regulatory insight, not theoretical compliance advice. Follow-the-sun execution with local regulatory expertise in both jurisdictions simultaneously.
Most IT consultancies can’t speak to FDA inspectors. Most quality consultancies can’t fix the systems. Most AI firms don’t understand GxP. USDM does all three.
The AI Center of Excellence combines USDM’s 25-year regulated technology track record with a purpose-built AI practice — operating on a Build-Sell-Deliver model with dedicated US and EU delivery PODs.
Start with a structured AI Readiness Assessment — fixed-fee, executive-ready output.
Six integrated practice areas — each addressing a distinct AI governance, validation, or deployment challenge unique to regulated life sciences. Click any service to expand details, deliverables, and timelines.
Six integrated practice areas — each addressing a distinct AI governance, validation, or deployment challenge unique to regulated life sciences. Click any service to expand details, deliverables, and timelines.
Structured diagnostic across six maturity dimensions — strategy, governance, data, talent, deployment, and ethics. Produces a calibrated AI maturity score, shadow AI inventory, peer benchmarks, and a prioritized roadmap. USDM’s validated methodology derived from 50+ life sciences AI engagements.
AI Maturity scorecard · Executive readiness brief · 90-day action roadmap · Use case pipeline
Implementation of USDM’s proprietary TRUST-AI governance framework — Transparent, Reliable, Unbiased, Secure, Tested, Accountable. Establishes AI policies, SOPs, risk classification, and governance committee structure aligned to FDA, EU AI Act, and ISO 42001.
AI governance SOP suite · RACI matrix · AI risk register · Board-ready risk posture report
Facilitated workshop using USDM’s AI Use Case Scoring Matrix to identify, score, and prioritize AI opportunities by business value, feasibility, and regulatory risk — followed by PoC delivery for top-priority candidates within GxP guardrails.
Scored use case portfolio · Executive decision brief · PoC build-out for 1–2 priority use cases
GxP-aligned validation strategies for AI/ML systems using FDA’s Computer Software Assurance framework — risk-based, documentation-right-sized, and designed for continuous SaaS release cycles. Includes LLM output validation and GAMP 5 Category 5 documentation.
AI validation strategy · IQ/OQ/PQ adapted for AI · LLM output validation package · Performance monitoring plan
Structured assessment and continuous monitoring of AI vendors and tools against USDM’s AI TPRM framework — covering model transparency, data governance, regulatory compliance, SLA adequacy, and contractual risk. OSINT-powered intelligence dashboards. Scalable to 150+ vendor portfolios.
Vendor risk profiles · TPRM scorecard · Procurement guidance · Contractual requirement templates
End-to-end EU AI Act compliance pathway — risk classification across all AI systems, Annex IV conformity assessment documentation, unified compliance mapping across EU AI Act + FDA + GDPR + ISO 42001, and ongoing regulatory intelligence monitoring.
AI system inventory & risk classification · Conformity assessment documentation · Unified multi-jurisdiction compliance matrix
Subscription-based ongoing AI governance replacing the need for a full-time internal AI governance function. Covers policy maintenance, regulatory monitoring, AI system intake review, TPRM continuous monitoring, and quarterly board reporting — all as a predictable monthly cost.
Monthly governance reports · Quarterly board briefings · Regulatory update alerts · New system intake assessments
USDM’s proprietary AI-powered GxP process automation platform built on ServiceNow — intelligent CAPA routing, automated deviation classification, predictive escalation, and automated regression testing. Fully validated, full audit trail, production-ready.
Deployed AI workflows · Automated test suite · Validation documentation · Labor reduction measurement
Fixed-scope, fixed-fee delivery in 4–12 week sprints. Ideal for assessments, framework builds, and PoC delivery. Clear deliverables, defined timelines, and executive-ready outputs at every milestone.
AGaaS, Cloud Assurance, and GxP Managed Services delivered as monthly subscriptions. Predictable cost, continuous compliance coverage, and no internal FTE overhead. Scales with your AI portfolio.
Flexible resource model combining US onshore expertise, EU regulatory knowledge, and nearshore efficiency. Typical cost reduction of 30–50% vs. all-onshore consulting. Deployed within 2–4 weeks.
USDM’s proprietary seven-pillar governance architecture — designed specifically for life sciences AI. Aligned to FDA CSA, EU AI Act Articles 9–15, ISO 42001, NIST AI RMF, and GAMP 5 Second Edition. Click each pillar to explore requirements and USDM capabilities.
AI systems in GxP environments must have documented, auditable decision logic. Regulators and auditors expect to understand how AI outputs are generated — and companies must be able to explain AI-driven decisions in human-interpretable terms. USDM implements explainability frameworks that satisfy FDA and EU AI Act Article 13 disclosure requirements.
USDM’s proprietary seven-pillar governance architecture — designed specifically for life sciences AI. Aligned to FDA CSA, EU AI Act Articles 9–15, ISO 42001, NIST AI RMF, and GAMP 5 Second Edition. Click each pillar to explore requirements and USDM capabilities.
AI systems must perform as intended — consistently, repeatably, and within defined boundaries. USDM applies FDA CSA risk-based validation principles to establish performance baselines, validate AI outputs, and maintain ongoing monitoring for drift and degradation across the model lifecycle.
IQ/OQ/PQ adapted for AI — GAMP 5 Category 5 approach
USDM’s proprietary seven-pillar governance architecture — designed specifically for life sciences AI. Aligned to FDA CSA, EU AI Act Articles 9–15, ISO 42001, NIST AI RMF, and GAMP 5 Second Edition. Click each pillar to explore requirements and USDM capabilities.
AI models trained on biased or non-ALCOA+ compliant data don’t just produce bad predictions — in a GxP context, they can generate biased outputs that influence regulatory submissions, patient safety decisions, and quality judgments. USDM’s bias assessment methodology addresses both algorithmic fairness and data integrity at the foundation.
USDM’s proprietary seven-pillar governance architecture — designed specifically for life sciences AI. Aligned to FDA CSA, EU AI Act Articles 9–15, ISO 42001, NIST AI RMF, and GAMP 5 Second Edition. Click each pillar to explore requirements and USDM capabilities.
AI systems introduce novel cybersecurity risks — LLM data leakage, prompt injection, model poisoning, and adversarial attacks — on top of existing GxP data security requirements. USDM integrates AI-specific cybersecurity controls with your existing GxP security framework and regulatory data integrity obligations.
Integration with SOC 2 / ISO 27001 / HIPAA control frameworks
USDM’s proprietary seven-pillar governance architecture — designed specifically for life sciences AI. Aligned to FDA CSA, EU AI Act Articles 9–15, ISO 42001, NIST AI RMF, and GAMP 5 Second Edition. Click each pillar to explore requirements and USDM capabilities.
Tested AI is validated AI — with documented evidence that the system performs as intended under all conditions relevant to its GxP use. USDM applies structured testing methodologies adapted from FDA CSA and GAMP 5 to produce inspection-ready validation packages for AI systems of every risk classification.
USDM’s proprietary seven-pillar governance architecture — designed specifically for life sciences AI. Aligned to FDA CSA, EU AI Act Articles 9–15, ISO 42001, NIST AI RMF, and GAMP 5 Second Edition. Click each pillar to explore requirements and USDM capabilities.
Human oversight is non-negotiable for high-risk AI in life sciences. EU AI Act Articles 14–15 and FDA’s AI/ML guidance both require documented human-in-the-loop controls, clear accountability structures, and formal governance mechanisms. USDM establishes the operating model that makes accountability real — not just documented.
USDM has catalogued 47+ validated AI use cases across the life sciences value chain. Each carries a GxP compliance pathway, risk classification, and implementation framework. Filter by domain to explore relevant opportunities.
AI-assisted SOP review, change control analysis, and CAPA drafting using validated LLM pipelines with full audit trail controls.
AI-augmented adverse event signal detection and case processing — with regulatory-compliant oversight controls and 21 CFR Part 314 alignment.
Intelligent classification of quality events by risk level — routing only high-complexity deviations through intensive investigation cycles.
AI-assisted outlier detection, protocol deviation identification, and site performance monitoring within validated eClinical environments per ICH E6 R3.
GenAI-assisted regulatory document drafting (CSRs, eCTD sections, labeling) with qualified reviewer oversight workflow and audit trail.
AI anomaly detection across GxP audit trails — surfacing ALCOA+ violations, backdating patterns, and data integrity risks pre-inspection.
AI-driven statistical process control, real-time deviation alerts, and predictive quality analytics for GMP manufacturing environments.
ML-powered analysis of genomic, proteomic, and clinical data to accelerate target selection and patient stratification in early research.
LLM-powered scientific content drafting with MLR workflow integration — maintaining promotional compliance while accelerating medical communications.
AI-assisted formulation modeling and chemistry, manufacturing, and controls optimization — accelerating development timelines.
AI-powered regulatory change monitoring across 50+ global health authorities — automated impact assessment and compliance framework updates.
Predictive analytics for supply chain disruption detection, demand forecasting, and API inventory optimization across global supplier networks.
OSINT-powered continuous monitoring of third-party vendors and AI tools — automated risk scoring and audit-ready qualification packages.
AI-powered sales forecasting, patient access analytics, and HCP engagement intelligence — compliant with Sunshine Act and privacy regulations.
Automated scientific literature surveillance, patent monitoring, and competitive landscape intelligence for research and regulatory strategy.
AI-assisted SOP review, change control analysis, and CAPA drafting using validated LLM pipelines with full audit trail controls.
Intelligent classification of quality events by risk level — routing only high-complexity deviations through intensive investigation cycles.
AI anomaly detection across GxP audit trails — surfacing ALCOA+ violations, backdating patterns, and data integrity risks pre-inspection.
OSINT-powered continuous monitoring of third-party vendors and AI tools — automated risk scoring and audit-ready qualification packages.
AI-augmented adverse event signal detection and case processing — with regulatory-compliant oversight controls and 21 CFR Part 314 alignment.
AI-assisted outlier detection, protocol deviation identification, and site performance monitoring within validated eClinical environments per ICH E6 R3.
GenAI-assisted regulatory document drafting (CSRs, eCTD sections, labeling) with qualified reviewer oversight workflow and audit trail.
AI-powered regulatory change monitoring across 50+ global health authorities — automated impact assessment and compliance framework updates.
AI-driven statistical process control, real-time deviation alerts, and predictive quality analytics for GMP manufacturing environments.
AI-assisted formulation modeling and chemistry, manufacturing, and controls optimization — accelerating development timelines.
ML-powered analysis of genomic, proteomic, and clinical data to accelerate target selection and patient stratification in early research.
Automated scientific literature surveillance, patent monitoring, and competitive landscape intelligence for research and regulatory strategy.
LLM-powered scientific content drafting with MLR workflow integration — maintaining promotional compliance while accelerating medical communications.
Predictive analytics for supply chain disruption detection, demand forecasting, and API inventory optimization across global supplier networks.
AI-powered sales forecasting, patient access analytics, and HCP engagement intelligence — compliant with Sunshine Act and privacy regulations.
Every AI use case is evaluated across three dimensions to determine priority and investment sequencing:
GxP impact, FDA/EU AI Act classification, patient safety proximity, inspection exposure
Four major regulatory frameworks are converging simultaneously — each with distinct requirements, timelines, and enforcement mechanisms. USDM’s unified compliance approach maps a single AI system across all four in one integrated assessment.
FDA’s Computer Software Assurance framework replaces documentation-heavy CSV with a risk-based, critical-thinking approach — establishing the primary validation pathway for AI/ML systems in GxP environments. The FDA AI/ML Action Plan provides supplemental guidance on AI in drug development, safety monitoring, and SaMD.
21 CFR Part 11 / Annex 11 compliance for AI-generated records
CSA guidance finalized 2022 · AI/ML Action Plan active · Enforcement ongoing
Warning Letter · Product approval delay · Market access restriction
Four major regulatory frameworks are converging simultaneously — each with distinct requirements, timelines, and enforcement mechanisms. USDM’s unified compliance approach maps a single AI system across all four in one integrated assessment.
The EU AI Act establishes the world’s first comprehensive AI regulatory framework — with high-risk classification directly applicable to AI systems in medical devices, pharmacovigilance, clinical decision support, and regulated quality processes. Life sciences companies face the most intensive compliance obligations under the Act.
Prohibited practices: Feb 2025 (active) · High-risk obligations: Aug 2026 · Full application: Aug 2027
Up to €35M or 7% of global annual turnover · Market access restriction
Four major regulatory frameworks are converging simultaneously — each with distinct requirements, timelines, and enforcement mechanisms. USDM’s unified compliance approach maps a single AI system across all four in one integrated assessment.
ISO 42001:2023 establishes international requirements for an AI Management System (AIMS) — providing the governance infrastructure that organizations need to implement, maintain, and continually improve responsible AI practices. Aligns closely with EU AI Act requirements and provides the operational backbone for TRUST-AI.
Published December 2023 · Emerging as de facto governance standard · EU AI Act alignment confirmed
No direct financial penalty · Provides compliance evidence for EU AI Act and FDA requirements
Four major regulatory frameworks are converging simultaneously — each with distinct requirements, timelines, and enforcement mechanisms. USDM’s unified compliance approach maps a single AI system across all four in one integrated assessment.
GAMP 5’s second edition explicitly addresses AI/ML systems in pharmaceutical manufacturing and quality environments — establishing Category 5 as the classification for AI systems with bespoke algorithms. Provides updated guidance on data integrity, life cycle management, and validation evidence for AI in GxP.
GAMP 5 2nd Ed. published 2022 · Actively referenced in FDA inspections · Industry standard
No direct financial penalty · Inspection finding risk · Part of FDA/EMA inspection expectations
EU AI Act officially in force. Six-month countdown begins for prohibited practice rules and GPAI model obligations.
Banned AI applications prohibited. General-purpose AI model obligations in force. European AI Office established and operational.
Full high-risk AI system compliance required: conformity assessments, Annex IV documentation, human oversight mechanisms, post-market monitoring. Life sciences AI in QMS, PV, SaMD contexts must comply. This is the critical deadline for most life sciences organizations.
All remaining provisions apply, including obligations for AI systems embedded in regulated products (MDR, IVD Regulation). Full enforcement capability across all member states.